Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-05-02FDA Approved: BORTEZOMIB — Original Application (Fresenius Kabi USA, LLC)
FDA approves Fresenius Kabi USA's generic bortezomib injection under Original Application. Indications include multiple myeloma and mantle c…
-
FDA approval · 2022-05-02FDA Approved: BORTEZOMIB — Original Application (BluePoint Laboratories)
FDA approved a generic version of bortezomib under an Original Application (ANDA210824) by BluePoint Laboratories.
-
FDA approval · 2022-05-02FDA Approved: BORTEZOMIB — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the original application for generic bortezomib by Zydus Pharmaceuticals USA Inc., enabling a generic version of the proteasome…
-
FDA approval · 2022-04-28FDA Approved: NINLARO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for NINLARO (ixazomib) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2022-04-26FDA Approved: EVOMELA — Supplemental Application (Acrotech Biopharma Inc)
FDA approved a supplemental application for EVOMELA (melphalan liposome injection) filed by Acrotech Biopharma Inc., updating the product la…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-04-20Clinical Trial Update: Effect of Vitamin C in Autologous Stem Cell Transplantations [Phase 2]
Phase 2 trial update evaluating the effect of Vitamin C in autologous stem cell transplantations for myeloma and lymphoma is completed.
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide [Phase 2]
Phase 2 trial evaluating elotuzumab plus lenalidomide for serologic relapse/progression on lenalidomide in multiple myeloma; study terminate…
-
FDA approval · 2022-04-05FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Sagent Pharmaceuticals)
The FDA approved a supplemental application for Zoledronic acid submitted by Sagent Pharmaceuticals, updating regulatory labeling per the su…
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment [Phase 2]
Phase 2 trial of isatuximab with bortezomib, cyclophosphamide, and dexamethasone, followed by maintenance with isatuximab and lenalidomide i…
-
CLINICAL_TRIALS trial_result · 2022-03-28Clinical Trial Update: A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor [Phase 2]
Phase 2 trial evaluating isatuximab combined with pomalidomide and dexamethasone in multiple myeloma patients who had one prior line includi…
-
EMA approval · 2022-03-25New gene therapy to treat adult patients with multiple myeloma
EMA announces a new gene therapy approved to treat adult patients with multiple myeloma.
-
FDA approval · 2022-03-22FDA Approved: EMPLICITI — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
The FDA approved a supplemental application for EMPLICITI (elotuzumab) from E.R. Squibb & Sons, L.L.C.
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating trametinib combined with the Akt inhibitor GSK2141795 in relapsed or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update reports on the safety and effectiveness of combining Nivolumab and Daratumumab in patients with multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma [Phase 2]
Phase 2 trial assessing accelerated infusion rate of daratumumab in relapsed and refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-11Clinical Trial Update: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 3]
Phase 3 study evaluating pomalidomide with low-dose dexamethasone in relapsed/refractory multiple myeloma is being conducted; final results …
-
CLINICAL_TRIALS trial_result · 2022-02-02Clinical Trial Update: Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of panobinostat and carfilzomib in relapsed/refractory multiple myeloma has completed with posted…
-
CLINICAL_TRIALS trial_result · 2022-02-01Clinical Trial Update: GEM-CLARIDEX: Ld vs BiRd [Phase 3]
Phase 3 trial update comparing LD vs BiRD regimens in multiple myeloma; status is unknown.
-
CLINICAL_TRIALS trial_result · 2022-02-01Clinical Trial Update: A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating melphalan flufenamide (melflufen) plus dexamethasone in relapsed/refractory multiple myeloma has been completed wit…
-
CLINICAL_TRIALS trial_result · 2022-01-28Clinical Trial Update: A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) [Phase 1, Phase 2]
Phase I/II study of Temferon in multiple myeloma with early relapse after frontline therapy; trial terminated with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: Optimising Renal Outcome in Myeloma Renal Failure [Phase 2]
Phase 2 trial update on optimizing renal outcome in myeloma-related kidney failure.
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients [Phase 2]
Phase 2 trial evaluating carfilzomib with daratumumab, lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myel…
-
CLINICAL_TRIALS trial_result · 2022-01-21Clinical Trial Update: Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens [Phase 1, Phase 2]
Clinical trial evaluating vorinostat, lenalidomide, and dexamethasone in multiple myeloma refractory to prior lenalidomide-containing regime…
-
CLINICAL_TRIALS trial_result · 2022-01-21Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with ixazomib for high-risk multiple myeloma has completed; resu…
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma [Phase 1, Phase 2]
A phase 1/2 clinical trial of CAR T-cell therapy for acute myeloid leukemia and multiple myeloma has terminated with results posted in 2022.